Persistent Asset Partners’s Vir Biotechnology VIR Stock Holding History

Persistent Asset Partners’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68.5K	Sell	225 -13	-5%	-$104	0.03%	254
2025 Q4	$20.9K	Buy	+238	New	+$1.42K	0.01%	312

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Persistent Asset Partners's VIR Position: Q1 2026 in Review

Persistent Asset Partners sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 63,550 shares — an estimated $506K sold.

Persistent Asset Partners first reported a position in VIR in Q4 2024 and held it in 2 quarters. The position peaked at $383K in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

Persistent Asset Partners reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
Persistent Asset Partners sold 63,550 Vir Biotechnology shares in Q1 2026, an estimated $506K.
Persistent Asset Partners first reported a position in Vir Biotechnology in Q4 2024 and held it in 2 quarters.
Persistent Asset Partners's Vir Biotechnology position peaked at $383K in Q4 2025.
251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.